Bettinger, Dominik ORCID: 0000-0002-8782-8729, Pinato, David J., Schultheiss, Michael, Sharma, Rohini, Rimassa, Lorenza ORCID: 0000-0001-9957-3615, Pressiani, Tiziana, Burlone, Michela E., Pirisi, Mario, Kudo, Masatoshi ORCID: 0000-0002-4102-3474, Park, Joong Won, Buettner, Nico, Neumann-Haefelin, Christoph, Boettler, Tobias ORCID: 0000-0002-1195-055X, Abbasi-Senger, Nasrin, Alheit, Horst, Baus, Wolfgang, Blanck, Oliver ORCID: 0000-0003-1391-1308, Gerum, Sabine, Guckenberger, Mathias, Habermehl, Daniel, Ostheimer, Christian, Riesterer, Oliver, Tamihardja, Joerg, Grosu, Anca-Ligia, Thimme, Robert, Brunner, Thomas Baptist and Gkika, Eleni (2019). Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer, 8 (4). S. 281 - 295. BASEL: KARGER. ISSN 1664-5553

Full text not available from this repository.

Abstract

Background and Aims: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC. Methods: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival. Results: Median OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, p = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT. Conclusions: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib. (c) 2018 S. Karger AG, Basel

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Bettinger, DominikUNSPECIFIEDorcid.org/0000-0002-8782-8729UNSPECIFIED
Pinato, David J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schultheiss, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sharma, RohiniUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rimassa, LorenzaUNSPECIFIEDorcid.org/0000-0001-9957-3615UNSPECIFIED
Pressiani, TizianaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Burlone, Michela E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pirisi, MarioUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kudo, MasatoshiUNSPECIFIEDorcid.org/0000-0002-4102-3474UNSPECIFIED
Park, Joong WonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buettner, NicoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neumann-Haefelin, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boettler, TobiasUNSPECIFIEDorcid.org/0000-0002-1195-055XUNSPECIFIED
Abbasi-Senger, NasrinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Alheit, HorstUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baus, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blanck, OliverUNSPECIFIEDorcid.org/0000-0003-1391-1308UNSPECIFIED
Gerum, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guckenberger, MathiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Habermehl, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ostheimer, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Riesterer, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tamihardja, JoergUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grosu, Anca-LigiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thimme, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brunner, Thomas BaptistUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gkika, EleniUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-160836
DOI: 10.1159/000490260
Journal or Publication Title: Liver Cancer
Volume: 8
Number: 4
Page Range: S. 281 - 295
Date: 2019
Publisher: KARGER
Place of Publication: BASEL
ISSN: 1664-5553
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CLINICAL-PRACTICE GUIDELINES; QUALITY-OF-LIFE; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-TUMORS; PHASE-I; RADIOTHERAPY; ABSCOPAL; OUTCOMES; BRIDGE; EFFICACYMultiple languages
Oncology; Gastroenterology & HepatologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/16083

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item